HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sen. Lautenberg Plans Toxic Substances Control Update Bill

This article was originally published in The Tan Sheet

Executive Summary

Introducing a bill to modernize the 36-year-old Toxic Substances Control Act is a priority for Senator Frank Lautenberg in the 113th Congress. Senator David Vitter might introduce his own industry-backed bill to modernize the act.

You may also be interested in...

Negatives Outweigh Positives In Toxic Substances Control Bill, Attorney Says

Senate legislation to update the Toxic Substances Control Act shows improvement over a 2010 bill, but its potential benefit does not measure up to the burden it would impose on industry, one attorney says.

Industry Cautions Against Modeling TSCA Reforms After REACH

While industry, NGOs, legislators and others agree that the 35-year-old Toxic Substances Control Act should be reformed, stakeholders disagree on whether to use the European Union's Registration, Evaluation, Authorization and Restriction of Chemicals as a guide.

Canada Responds To Children’s OTC Pain Reliever Shortage Linked To Consumers ‘Panic Buying’

Shortage began in August and has increased the onset of cough/cold season due to consumers’ “stockpiling/panic buying” in response to high levels of activity in COVID-19, RSV, seasonal flu and other viruses, according to Canadian Pharmacists Association. Health Canada has approved imports of Haleon and J&J children’s pain relievers.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts